Semin Thromb Hemost 2006; 32(1): 077-078
DOI: 10.1055/s-2006-933343
ERRATA

Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The P2 Receptors and Congenital Platelet Function Defects

Marco Cattaneo
Further Information

 Professor
Marco Cattaneo

Unit of Hematology and Thrombosis, Ospedale San Paolo, DMCO University of Milan

Via di Rudinì, 8, 20142 Milan, Italy

Email: marco.cattaneo@unimi.it

Publication History

Publication Date:
15 February 2006 (online)

Table of Contents

    In the above-mentioned article, published in Seminars in Thrombosis and Hemostasis 2005; Volume 31, Number 2, pages 168-173, page 170, paragraph 1, line 3 should read:

    P2Y12 is the target of efficacious antithrombotic agents like ticlopidine and clopidogrel,2,32 which are already used in clinical practice, and the AR-C compounds,33 one of which is currently under evaluation in clinical trials.

     Professor
    Marco Cattaneo

    Unit of Hematology and Thrombosis, Ospedale San Paolo, DMCO University of Milan

    Via di Rudinì, 8, 20142 Milan, Italy

    Email: marco.cattaneo@unimi.it

     Professor
    Marco Cattaneo

    Unit of Hematology and Thrombosis, Ospedale San Paolo, DMCO University of Milan

    Via di Rudinì, 8, 20142 Milan, Italy

    Email: marco.cattaneo@unimi.it